Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT

NCT05914675 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

21

Enrollment

OTHER

Sponsor class

Conditions

The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation

Interventions

DRUG: Letermovir

Sponsor

Institute of Hematology & Blood Diseases Hospital, China